Stephen Thompson

Stephen is a founding partner of Brandon Capital Partners.

Before moving to Australia, Stephen was a Director of Apax Partners based in London. Previously, he fulfilled roles in product development with UK biotechnology company Cantab Pharmaceuticals. Earlier, Stephen spent ten years as a research immunologist in London and California.

Stephen is currently a director of; Longas Technologies, MecRx, Myricx Pharma, OncoRes Medical, Respirion Pharmaceuticals and Vaxxas. Stephen was a former director of Elastagen, (acquired by Allergan in 2018).

Stephen has a Bachelor of Science (Honours) from Chelsea College London, a PhD in Immunology from Kings College London and an MBA, specialising in Entrepreneurship, from Imperial College London. Stephen is a Graduate of the Australian Institute of Company Directors and a former director of the Australian Investment Council (AIC).